Evidence map›Paper›PMID 35781139›Full record

Observational studyJournal of the Egyptian National Cancer Institute2022

Effect of treatment interruptions and outcomes in cancer patients undergoing radiotherapy during the first wave of COVID-19 pandemic in a tertiary care institute.

Sandip Kumar Barik, Arvind Kumar Singh, Minakshi Mishra, Adhar Amritt, Dinesh Prasad Sahu, Saroj Kumar Das Majumdar, Dillip Kumar Parida

Open access · diamondAbstract readObservational Study
In one paragraph

Observational study in Journal of the Egyptian National Cancer Institute, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Review
  5. Article
  6. OralCancers · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sandip Kumar BarikDepartment of Radiotherapy, All India Institute of Medical Sciences, Sijua P.O Patrapada, Bhubaneswar, Odisha, 751019, India. sandip.barik1@gmail.com.ORCID http://orcid.org/0000-0001-8573-4449
Arvind Kumar SinghDepartment of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
Minakshi MishraDepartment of Radiotherapy, All India Institute of Medical Sciences, Sijua P.O Patrapada, Bhubaneswar, Odisha, 751019, India.
Adhar AmrittDepartment of Radiotherapy, All India Institute of Medical Sciences, Sijua P.O Patrapada, Bhubaneswar, Odisha, 751019, India.
Dinesh Prasad SahuDepartment of Community Medicine and Family Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India.
Saroj Kumar Das MajumdarDepartment of Radiotherapy, All India Institute of Medical Sciences, Sijua P.O Patrapada, Bhubaneswar, Odisha, 751019, India.
Dillip Kumar ParidaDepartment of Radiotherapy, All India Institute of Medical Sciences, Sijua P.O Patrapada, Bhubaneswar, Odisha, 751019, India.
All India Institute of Medical Sciences Bhubaneswar · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCOVID-19 patients with cancer had poorer outcomes due to immunosuppression during cancer care, poor general condition, and other comorbidities. The study was conducted to present the real-world analysis of the effect of treatment interruptions on the outcomes of patients treated with radiation therapy during the first wave of the COVID-19 pandemic in a tertiary care institute in India. MATERIALS AND

methodsThe study is a retrospective observational cohort study on cancer patients undergoing radiation therapy from March 2020 to January 2021. The study's primary outcome was to analyze the effect of treatment interruptions on the outcomes of patients treated with radiation therapy during the first wave of COVID-19 pandemic.

resultsBetween March 2020 to January 2021, 218 eligible patients undergoing radiation therapy were found for the study. Among the 218 patients, 25 patients (11.47%) were found positive for COVID-19, while 193 patients (88.53%) were negative for COVID-19. Among COVID-19-positive patients, ten patients had < 3 weeks of treatment interruption, while 15 patients had > 3 weeks of treatment interruptions. After recovering from COVID-19, treatment was resumed and completed for 15 (60.00%) of the COVID-19-positive patients. In comparison, 13 patients (52.00%) were lost to follow-up. Three of the COVID-19-positive patients died. The disease was clinically controlled in 12 (48.00%) of the COVID-19-positive patients, and the patients reported locoregional disease progression in 10 (40.00%). Among the 193 COVID-19-negative patients, 32 patients (16.58%) had treatment interruption. Twelve patients (37.50%) had treatment interruptions for less than 1 week. There was a significant difference in the delay of radiation treatment delivery by 2 weeks (11 fractions) in COVID-19-positive patients compared to only two fractions delay in COVID-19-negative patients.

conclusionCOVID-19 impacted the treatment outcomes in both COVID-19-positive and COVID-19-negative cohorts of patients. There was a longer duration of treatment interruptions in the COVID-19-positive patients, leading to fewer patients completing the radiation treatment and thereby increased locoregional disease progression. There was a significant difference in the delay in treatment between the two groups.

Indexed as

COVID-19NeoplasmsDisease ProgressionHumansPandemicsRetrospective StudiesTertiary Health CareCancerCOVID-19RadiotherapyTreatment interruptionTreatment outcomes

Identifiers

PMID35781139
PMCPMC9251018
OpenAlexW4283803445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.